PolyNovo Limited (PNV.AX)
PolyNovo Limited
320 Lorimer Street
Unit 2
Port Melbourne, VIC 3207
Australia
61 3 8681 4050
https://www.polynovo.com
Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 237
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Swami Raote BPHARM, M.B.A. | CEO & Director | 868.06k | N/A | N/A |
| Mr. Jan-Marcel Gielen C.A. | CFO & Company Secretary | 291.63k | N/A | N/A |
| Dr. David McQuillan Ph.D. | Chief Technical & Scientific Officer | 444.21k | N/A | N/A |
| Mr. Philip Scorgie | Chief Information Officer | 239.25k | N/A | N/A |
| Mr. Ahmed Hassan | Director of Operations | N/A | N/A | N/A |
| Ms. Monica Benyk | Director of People | N/A | N/A | N/A |
| Dr. Tim Moore | Principal Scientist | 144.25k | N/A | N/A |
| Mr. Edward Graubart | President of North America | N/A | N/A | N/A |
| Dr. Joseph F. Amaral M.D. | Chief Medical Officer | N/A | N/A | 1956 |
Description
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Corporate governance
PolyNovo Limited’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 1; Compensation: 9.
